Klin Onkol 2015; 28(6): 444-449. DOI: 10.14735/amko2015444.
Summary
Background: Metastatic melanoma is a malignancy with one of the highest mortality rates. However, with the introduction of new drugs during the last decade, the prognosis of patients began to improve. Ipilimumab is one of the first so- called modern drugs in melanoma treatment. The therapy is often complicated by adverse effects which are referred as immune-related adverse events due to its mechanism of action. Case: We present a case of 68-year- old women with metastatic melanoma who underwent treatment with ipilimumab. The patient encountered several adverse events during the treatment. Some of them are quite common (e.g. skin aff ections), others (e.g. endocrinopathies) are less frequent. Conclusion: This case study highlights the need for close observation not only during the actual treatment with ipilimumab, but also several weeks or months after the last dose. This case study also demonstrates further need of education of doctors who do not usually come in to contact with such patients
